Results 141 to 150 of about 51,036 (300)

Record-linkage for pharmacovigilance in Scotland

, 1999
Record-linkage is the linkage of patient-specific information that is stored separately. Recent advances in computerization have meant that record-linkage techniques in medical research are increasingly being used and refined.
Evans, Josie, MacDonald, Thomas M, MacDonald, Thomas M., Evans, Josie M.M.   +3 more
core   +1 more source

Joint medicine-information and pharmacovigilance services could improve detection and communication about drug-safety problems

, 2014
Jan Schjøtt,1–3 Jenny Bergman3 1Section of Clinical Pharmacology, Laboratory of Clinical Biochemistry, Haukeland University Hospital, 2Institute of Clinical Science, Faculty of Medicine and Dentistry, University of Bergen, 3Regional ...
Schjøtt J, Bergman J
core  

Is pharmacovigilance of biologicals cost-effective?

, 2018
Pharmacovigilance is an essential part of the post-marketing surveillance of new biologicals. It not only requires a substantial investment of the marketing authorization holder but also of the clinical field to provide accurate safety information. Hence,
Claus, Barbara
core   +1 more source

Unintended Pregnancies and Breastfeeding Studies during Central Nervous System Drug Development: How Are they Handled, Is There Room for Improvement?

Clinical Pharmacology &Therapeutics, EarlyView.
Pregnant and breastfeeding individuals are routinely excluded from clinical drug development, creating persistent evidence gaps in pharmacology, safety, and dosing. Despite mandatory contraception and pregnancy testing, unintended pregnancies occur, particularly during the development of central nervous system (CNS) medicines used by women of ...
Sam Schoenmakers, Charlotte Bakker, Alexandra Ganev, Florence Butlen‐Ducuing, Corinne S. de Vries   +4 more
wiley   +1 more source

Collaboration in pharmacovigilance: lamotrigine and fatal severe cutaneous adverse reactions – a review of spontaneous reports

, 2017
Neil Brickel,1 Haris Shaikh,1 Andrew Kirkham,2 Greg Davies,1 Michelle Chalker,1 Pascal Yoshida3 1Global Clinical Safety and Pharmacovigilance, GlaxoSmithKline, Uxbridge, Middlesex, UK; 2Classic and Established Products, GlaxoSmithKline, Brentford ...
Kirkham A, Yoshida P, Brickel N, Davies G, Shaikh H, Chalker M   +5 more
core  

General architecture for the distributed pharmacovigilance platform.

, 2013
General architecture for the distributed pharmacovigilance platform.
Tiago Nunes (495624), Anna Bauer-Mehren (173597), Ferran Sanz (89706), Paul Avillach (173608), Bharat Singh (173621), Ernst Ahlberg (495628), Maria Carmen Carrascosa (495627), Scott Boyer (173647), Pedro Lopes (97002), Erik van Mulligen (451345), Gayo Diallo (173632), José Luis Oliveira (451346), David Campos (495625), Johan van der Lei (451352), Jordi Mestres (168498), Jan Kors (390655), Carlos Diaz (495629), Laura Ines Furlong (495626)   +17 more
core   +1 more source

Long‐term cardiovascular outcomes of immune checkpoint inhibitor‐related myocarditis: A large single‐centre analysis

ESC Heart Failure, Volume 12, Issue 2, Page 1237-1245, April 2025.
Abstract Aims Immune checkpoint inhibitors (ICI) are the cornerstone of modern oncology; however, side effects such as ICI‐related myocarditis (irM) can be fatal. Recently, Bonaca proposed criteria for irM; however, it is unknown if they correlate well with cardiovascular (CV) ICI‐related adverse events.
Lorenzo Braghieri, Ahmad Gharaibeh, Lubika Nkashama, Abdelrahman Abushouk, Osama Abushawer, Amir Mehdizadeh‐Shrifi, Bianca Honnekeri, Cassandra Calabrese, Venu Menon, Pauline Funchain, Patrick Collier, Diego Sadler, Rohit Moudgil   +12 more
wiley   +1 more source

The gut microbiome and drug‐resistant epilepsy: Microbiome–antiseizure medication interactions and implications for pharmacoresistance

Epilepsia Open, EarlyView.
Abstract Drug‐resistant epilepsy (DRE) affects approximately one‐third of patients with epilepsy and represents a major unmet clinical need. While traditional hypotheses of pharmacoresistance have focused on alterations in drug targets, efflux transporter overexpression, and intrinsic disease severity, the gut microbiome has recently emerged as a ...
Khaled Zammar, Majd A. AbuAlrob, Musab Ali, Simona Lattanzi, Boulenouar Mesraoua   +4 more
wiley   +1 more source

Engineering mRNA‐LNP Medicines for the Ageing Brain: Opportunities and Challenges for Neurodegenerative Diseases

Exploration, EarlyView.
This review highlights recent advances in engineering messenger RNA (mRNA)‐lipid nanoparticles (LNPs) to cross the ageing blood–brain barrier and target neurodegenerative diseases. It outlines design principles, delivery routes, and translational challenges, charting a roadmap towards clinical application of mRNA‐LNP therapeutics for neurodegenerative ...
Abdel Ali Belaidi, Denzil L. Furtado, Francesca Alves, Rebecca M. Nisbet, Scott Ayton, Ashley I. Bush   +5 more
wiley   +1 more source

Bridging Worlds: Can Evidence, Regulation and Indigenous Leadership Shape the Future of Traditional, Complementary and Integrative Medicine?

The International Journal of Health Planning and Management, EarlyView.
ABSTRACT Background and need As the WHO Global Traditional Medicine Strategy 2025–2034 encourages countries to consider integrating traditional, complementary and integrative medicine (TCIM) into health systems, there is a need to clarify the principal scientific, regulatory, ethical, and governance challenges involved. Renewed global attention to TCIM,
Abdul‐Basit Abdul‐Samed, Dina Balabanova, Neil Spicer, Martin McKee   +3 more
wiley   +1 more source